In 2017, Fiedor and collaborators identified super-active human leptin antagonists (SHLA, D23L/L39A/D40A/F41A mutant), triple Lan1, and quadruple Lan2 leptin mutein as promising treatments for ovarian cancer, particularly the folliculoma type. This evidence concerns the gene LEP and ovarian carcinoma.